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1. INTRODUCTION
Two-stage designs have commonly been used in studies of Alzheimer’s disease (AD) because of the
relatively low prevalence of the disease and high cost of ascertaining a diagnosis. In the ﬁrst stage,
a large sample of subjects are screened for AD with inexpensive screening tests. In the second stage,
a subset of the screened subjects are selected for the clinical diagnosis by a more extensive but more
expensive clinical assessment. The probability of selection for the clinical assessment depends on the
screening result from the ﬁrst stage, as well as other factors, such as subject’s age. Furthermore, not
all selected subjects have the clinical diagnosis because some subjects may refuse and others are unable
to be clinically assessed.
For example, in the motivational example, as reported in Zhou and Higgs (2000), Hendrie and his
colleagues employed a two-stage design to study the role of environmental risk factors for development
of dementia in two black populations in Indianapolis, USA, and Ibadan, Nigeria. The study used a
two-stage design. The ﬁrst stage consisted of screening a large sample of subjects for dementia with
the screening instruments, and the second stage consisted of selecting a small number of the screened
subjects for the clinical diagnosis of dementia by a clinical assessment, which consisted of a neurological
examination, a neuropsychological test battery, laboratory tests, CT scans, and a detailed interview with
a relative of the subject. Selection for the clinical assessment was based on the score of the screening
instruments and the age of a subject. All subjects who were screened into the ‘poor performance’
category were selected for the clinical assessment; a subject who was screened into the ‘intermediate
performance’ category had the 50% chance of being selected for the clinical assessment; and a subject
who was screened into the ‘good performance’ group had the 5% chance of being selected for the
clinical assessment. In addition, a stratiﬁed random sample was taken in the ‘good performance’ group,
selecting 75% from those age 75 years and older in order to have enough older subjects. The clinical
diagnosis, however, was not obtained for all subjects who were selected for disease veriﬁcation because
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some subjects were unable to be clinically assessed, while others refused.
We are interested in comparing the accuracy of a new screening test (T1) with that of a standard
screening test (T2) for subjects age 75 years or older. The standard test is based on results from
the cognitive test only; and the new test uses information from the cognitive assessment given to the
subject as well as informant data from someone who knows the subject. Table 1 displays the resulting
classiﬁcation data in Indianapolis and Ibadan for subjects who were 75 years or older.
TABLE 1 GOES HERE
It has been shown that inferences on the accuracy of screening tests that use only veriﬁed cases
may result in veriﬁcation bias. Under the ignorable veriﬁcation bias assumption that the probability of
selection for veriﬁcation depends only on the observed data, Zhou and Higgs (2000) proposed a maximum
likelihood (ML) approach for comparing the accuracies of two tests while correcting for veriﬁcation bias.
However, if the veriﬁcation mechanism depends on unobserved variables that are related to the
disease status, the veriﬁcation mechanism is not ignorable. For example, if selected subjects who refuse
to be veriﬁed are likely demented, the veriﬁcation mechanism most likely depends on the unobserved
disease status and hence is non-ignorable. If the veriﬁcation mechanism is non-ignorable, the method
proposed in Zhou and Higgs (2000) cannot be applied to assess the relative accuracy of two screening
tests. Zhou and Castelluccio (2003) have developed a general approach for comparing the relative
accuracy of two screening tests in the presence of non-ignorable veriﬁcation bias.
In this paper, we apply the method of Zhou and Castelluccio (2003) to comparing the relative
accuracy of two screening tests in a two-stage design study in the presence of non-ignorable veriﬁcation
bias. This paper is organized as follows. In Section 2, we introduce notation and parameters of interest.
In Section 3, we propose a particular model for the non-ignorable veriﬁcation mechanism and discuss an
estimation method under the assumed non-ignorable veriﬁcation bias model. In Section 4, we contrast
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the diﬀerence between ML estimates under the ignorable veriﬁcation bias assumption and ones derived
under a non-ignorable veriﬁcation bias model and study eﬀects of non-ignorability on ML estimates
for ROC curve areas. In Section 5, we present results from the analysis of our AD data set using the
proposed methods.
2. Notation and Parameters of Interest
We denote ordinal-scale responses of two tests by T1 and T2, ranging from 1 to K. We let D
and V denote two indicator variables for the true disease status and disease veriﬁcation of a patient,
respectively. Here D = 1 for a diseased patient and 0 otherwise, and V = 1 for a veriﬁed patient and 0
for a non-veriﬁed patient. With such notation, we can display the observed data in Table 2.
Table 2 goes there
We let A1 and A2 denote the areas under the ROC curves of the screening test 1 and screening test
2, respectively, under the trapezoidal rule. If we let φ1jk = P (T1 = j, T2 = k) and φ2jk = P (D = 1 |
T1 = j, T2 = k), we can show that A1 and A2 are functions of φ1jk and φ2jk:
A1 =
1
γ(1− γ) [
K−1∑
j=1
K∑
k=1
(1− φ2jk)φ1jk
K∑
l=j+1
K∑
k=1
φ2lkφ1lk + (1/2)
K∑
j=1
K∑
k=1
(1− φ2jk)φ1jk
K∑
k=1
φ2jkφ1jk], (1)
and
A2 =
1
γ(1− γ) [
K−1∑
k=1
K∑
j=1
(1− φ2jk)φ1jk
K∑
l=k+1
K∑
j=1
φ2jlφ1jl + (1/2)
K∑
l=1
K∑
j=1
(1− φ2jl)φ1jl
K∑
j=1
φ2jlφ1jl], (2)
respectively, where γ = P (D = 1) =
∑K
j,l=1 φ1jlφ2jl.
Our statistical problem is to perform hypothesis testing about the two ROC curve areas and to
construct a conﬁdence interval for the diﬀerence in two ROC areas, A1 −A2.
3. Estimation Procedure
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Without the ignorable veriﬁcation bias assumption, we have to model the veriﬁcation mechanism to
draw a valid inference about the ROC curves and their areas of two screening tests. Let W be a (p+1)
dimensional vector of covariates, derived from the test results T1 and T2. Zhou and Castelluccio (2002)
have proposed the following non-ignorable veriﬁcation bias model:
logitP (V = 1 | T1, T2, D) = W ′β + αD, (3)
where β is a column vector of p + 1 parameters, and α is a scalar parameter.
Because of possible several local maximum likelihood estimates and boundary solutions, Zhou and
Castelluccio (2002) proposed a proﬁle maximum likelihood method for ﬁnding the global ML estimates.
We next introduce this proﬁle ML approach.
For the problem under consideration, the observed data consist of the two test results and true
disease status for a veriﬁed patient and only the two test results for an unveriﬁed patient. Denote
n =
∑K
j,l=1 njl, φ1 = (φ111, . . . , φ1(K−1)K)′, φ2 = (φ211, . . . , φ2KK)′, and φ = (φ
′
1,φ
′
2)
′. Let Vi, T
(i)
1 ,
T
(i)
2 , Di be the values of V , T1, T2, and D for the ith patient, respectively. Let
∑
Vi=1 denote a sum
over all cases in which Vi = 1 and let
∑
Vi=0 denote a sum over all cases in which Vi = 0.
Without the ignorable veriﬁcation bias assumption, a valid likelihood needs to be based on the data
V,D,W if V=1 and V,W if V=0, and the resulting log-likelihood function is given by
l(α,β,φ) =
K∑
j,l=1
[sjl log(ψ1jlφ2jl)+rjl log(ψ0jl(1−φ2jl))+ujl log((1−ψ1jl)φ2jl+(1−ψ0jl)(1−φ2jl))+njl log φ1jl],
(4)
where
ψ1jl = P (V = 1 | T1 = j, T2 = l,D = 1) = exp(W ′jlβ + α)/(1 + exp(W ′jlβ + α)),
and
ψ0jl = P (V = 1 | T1 = j, T2 = l,D = 0) = exp(W ′jlβ)/(1 + exp(W ′jlβ)).
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If we denote
l1(φ1) =
K∑
j,l=1
njl log φ1jl
and
l2(α,β,φ2) =
K∑
j,l=1
[sjl log(ψ1jlφ2jl)+ rjl log(ψ0jl(1−φ2jl))+ujl log((1−ψ1jl)φ2jl +(1−ψ0jl)(1−φ2jl))],
(5)
we can write l(α,β,φ) = l1(φ1) + l2(α,β,φ2). Therefore, maximizing l1(φ1) with respect to φ1, we
obtain the ML estimates for φ1jl as φˆ1jl = njl/n. We can obtain the ML estimates for the remaining
parameters, α, β, and φ2, by maximizing the log-likelihood l2(α,β,φ2).
By considering (V,D,W ) as complete-data, we can use the expectation-maximization (EM) algo-
rithm to ﬁnd ML estimates. Because the log-likelihood may have the several local maxima and boundary
solutions, the direct use of the EM algorithm may fail to ﬁnd the global ML estimates. If we knew the
value of α, it would be easier to estimate the remaining parameters, β and φ2. Therefore, we propose
to combine the proﬁle method and the EM algorithm to ﬁnd the global ML estimates for α, β, and φ2.
Speciﬁcally, we choose a set of α values. At each of the selected α values, we use the EM algorithm
to ﬁnd the ML estimates βˆ(α) and φˆ2(α), and we compute the proﬁle likelihood for α as lP (α) =
l(α, βˆ(α), φˆ2(α)), where l is given by Equation 4. Then, we ﬁnd the value of α that maximizes the
proﬁle likelihood with respect to α and the corresponding values for βˆ(α) and φˆ2(α). See Zhou and
Castellucio (2003) for a detailed description on the proﬁle EM method.
4. Likelihood-based inferences
After obtaining the ML estimators αˆ, βˆ, and φˆ for α, β, and φ, we can derive the ML estimators
for the non-parametric ROC curves of the two tests by substituting the unknown parameters in (1) and
(2) with their ML estimators.
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We may also use the likelihood-based method for testing the null hypothesis that H0 : A1 = A2
and for constructing conﬁdence intervals for the diﬀerence A1 −A2. By substituting the ML estimates
into (1) and (2), we obtain the ML estimators, Aˆ1 and Aˆ2, for the areas under the ROC curves of the
screening tests 1 and 2, respectively.
To ﬁnd the asymptotic covariance matrix of Aˆ1 and Aˆ2, we ﬁrst compute the expected Fisher in-
formation matrix for α, β, φ1, and φ2. Observe that we can write l(φ1,φ2) as the sum of l1(φ1) and
l2(α,β,φ2) and that the vectors φ1 and (α,β,φ2) are distinct. Therefore, the expected Fisher infor-
mation matrix for (α,β,φ1,φ2) is diag(I1(φ1), I2(α,β,φ2)), where I1(φ1) and I2(φ2) are the expected
Fisher information matrices for l1(φ1) and l2(α,β,φ2), respectively. Then, using the delta method
(Agresti, pp. 56-58, 1990) we ﬁnd a consistent estimator for the covariance matrix of Aˆ1 and Aˆ2, and
denote its (k, j)th element by νˆkl. Using the statistic,
Z = (Aˆ1 − Aˆ2)/
√
νˆ11 + νˆ22 − 2νˆ12,
we can test the null hypothesis that A1 = A2, basing the large-sample normal distribution of ML
estimators. Similarly we can derive a (1− α)% conﬁdence interval for A1 −A2 as
[Aˆ1 − Aˆ2 − z1−α/2
√
νˆ11 + νˆ22 − 2νˆ12, Aˆ1 − Aˆ2 + z1−α/2
√
νˆ11 + νˆ22 − 2νˆ12],
where z1−α is the (1− α/2)100th percentile of the standard normal distribution.
5. Comparison of ML estimates with and without the ignorable assumption
From Section 3 we see that without the ignorable veriﬁcation bias assumption, the valid log-likelihood
function is given by
lNonMAR(α,β,φ) =
K∑
j,l=1
[sjl log(ψ1jlφ2jl)+rjl log(ψ0jl(1−φ2jl))+ujl log((1−ψ1jl)φ2jl+(1−ψ0jl)(1−φ2jl))]+
K∑
j,l=1
njl log φ1jl], (6)
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where ψ1jl = P (V = 1 | T1 = j, T2 = l,D = 1) = ψ1jl(α, β), andψ0jl = P (V = 1 | T1 = j, T2 = l,D =
0) = ψ0jl(α, β).
If we assume the veriﬁcation bias is ignorable (e.g. α = 0), we obtain the following valid log-likelihood
function,
lMAR(β,φ) =
K∑
j,l=1
[sjl log(φ2jl) + rjl log(1− φ2jl)]+
K∑
j,l=1
[(sjl + rjl) log(ψjl) + ujl log(1− ψjl) + njl log φ1jl], (7)
where ψjl = P (V = 1 | T1 = j, T2 = l).
From (6) and (7), we see that the ML estimate for φ1jl is equal to the same expression, njl/n,
with or without the ignorable veriﬁcation bias assumption. However, the ML estimates for φ2jl’s will
be diﬀerent, depending on whether we assume the ignorable veriﬁcation bias. Under the ignorable
veriﬁcation bias assumption, the valid log-likelihood can be written as three separate terms, the ﬁrst
one involving only the parameters φ2jl’s, the second one involving only the parameters φ1jl’s, and the
third one involving only the veriﬁcation mechanism parameters ψjl’s. Therefore, the ML estimates for
φ2jl’s under the ignorable veriﬁcation bias assumption do not depend on ψjl’s, the parameters for the
veriﬁcation bias mechanism. However, without the ignorable veriﬁcation bias assumption, the valid
log-likelihood cannot be separated into a term that involves only the parameters φ2jl’ and a diﬀerent
term that involves only the veriﬁcation bias mechanism parameters. Therefore, the ML estimates for
φ2jl’s will depend on the estimated values of the parameters α and β in a non-ignorable model. Hence,
although the ROC curve area does not depend on model parameters α and β for the veriﬁcation
mechanism and depends only on φ1jl’s and φ2jl’s, without the ignorable veriﬁcation bias assumption,
the parameters α and β can still aﬀect the ROC curve area through their eﬀects on φ2jl; sometime their
eﬀects can be dramatic. We will further discuss this point when we analyze our motivating data set.
6. Results on Screening for Alzheimer’s Disease Data
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Let A1 and A2 be the areas under the ROC curves of the new screening test and the standard
screening test in a particular site (Indianapolis or Ibadan), respectively. We wish to know whether the
two screening tests are same in a particular site (Indianapolis and Ibadan).
We proposed the following model for the non-ignorable veriﬁcation mechanism:
logitP (V = 1 | W,D) = β0 + β1I[T1=1] + β2I[T1=2] + β3I[T2=1] + β4I[T2=2] + αD, (8)
This model assumes that no interactions between T1 and T2 can aﬀect the veriﬁcation mechanism.
To apply the proﬁle likelihood approach described in Section 3, we need to choose the set for α. We
chose this set to be between -8 and +8, with an increment value of 0.5; that is, α = −8 + 0.5 ∗ i, i =
1, . . . , 32. With this chosen set, we used the proﬁle approach described in Section 3 to ﬁnd the ML
estimates for α, β, and φ. To avoid a computational problem due to too many zero cells in the data, we
added a small number of 0.3 to the data given in Table 1 before we ran our proﬁle likelihood algorithm,
and we summarized the resulting proﬁle ML estimates for α, β, and φ in Table 3.
Table 3 goes here
Replacing unknown φ by their ML estimates in Equations 1 and 2, we obtained the ML estimates for
the ROC curve areas of the two screening tests, separately for Indianapolis and Ibadan sites. We then
calculated the associated covariance matrices by Fisher’s information matrix. We summarized those
results in Table 4, which also included 95% conﬁdence intervals for the diﬀerences between two ROC
curve areas.
Table 4 goes here
For comparison purposes, we also included the inference results under the ignorable veriﬁcation bias
assumption in Table 4.
To assess the goodness-of-ﬁt of this non-ignorable veriﬁcation bias model (8), we derived the following
Pearson’s goodness-of-ﬁt statistic. We assume that our data, given in Table 1, follow a multinomial
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distribution with the cell probabilities, πjl1 = P (T1 = j, T2 = l,D = 1, V = 1), πjl2 = P (T1 = j, T2 =
l,D = 0, V = 1), and πjl3 = P (T1 = j, T2 = l, V = 0). Under the proposed non-ignorable veriﬁcation
mechanism model, we see that the cell probabilities πjlk’s are functions of the parameters, α, β, φ1,
and φ2, and we can write them as πjlk(α,β,φ). The total number of unknown parameters in the model
is p+2K2. Let πˆjlk = πjlk(αˆ, βˆ, φˆ) be the ML estimate of πjlk(α,β,φ), where αˆ, βˆ, and φˆ are the ML
estimates of α, β, and φ, respectively, under the non-ignorable veriﬁcation bias model. For a formal
goodness-of-ﬁt test, we proposed the following Pearson’s test statistic:
χ2obs =
K∑
j,l=1
[
(sjl − nψˆ1jlφˆ1jlφˆ2jl)2
nψˆ1jlφˆ1jlφˆ2jl
+
(rjl − nψˆ0jlφˆ1jl(1− φˆ2jl))2
nψˆ0jlφˆ1jl(1− φˆ2jl)
]+
K∑
j,l=1
[ujl − n(ψˆ1jlφˆ1jlφˆ2jl + ψˆ0jlφˆ1jl(1− φˆ2jl))]2
n(ψˆ1jlφˆ1jlφˆ2jl + ψˆ0jlφˆ1jl(1− φˆ2jl))
.
From Table 3 we see the non-ignorable veriﬁcation mechanism operates slightly diﬀerent in the
Indianapolis and Ibadan sites. From the values of the goodness-of-ﬁt statistics, we concluded that the
proposed non-ignorable veriﬁcation bias models ﬁt the data well in both Indianapolis and Ibadan sites.
From Table 4 we also see that the ML estimates for the ROC curve areas can be dramatically
diﬀerent, depending on whether the ignorable veriﬁcation bias is assumed. For example, the estimated
ROC curve area for the ﬁrst screening test in the Indianapolis site is 0.87 under the ignorable veriﬁcation
bias assumption and is reduced to 0.69 under the non-ignorable veriﬁcation bias model. Similarly, in
the Ibadan site, the estimated ROC curve area of the ﬁrst screening test derived under the ignorable
veriﬁcation bias assumption is much lower than the one derived under the non-ignorable veriﬁcation bias
model. We also note that the variance and covariance estimates under the non-ignorable veriﬁcation
bias model tend to be larger than the ones derived under the ignorable veriﬁcation bias assumption;
this phenomena is what we expect since we have more parameters to estimate under a non-ignorable
veriﬁcation bias model than under the ignorable veriﬁcation bias assumption.
However, the conclusion on the signiﬁcant diﬀerence between the two ROC curve areas is unchanged,
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regardless whether we assume the ignorable veriﬁcation bias or use a non-ignorable veriﬁcation bias
model. To assess the sensitivity of adding a constant to our data, we have tried to add diﬀerent small
constants, and our results did not change.
7. DISCUSSION
In two-stage studies of Alzheimer’s disease, the veriﬁcation bias is a serious problem in estimation
of the accuracy of screening tests.
In this paper, we analyzed a particular data set from a two-stage study of dementia in two diﬀerent
sites under both the ignorable veriﬁcation bias assumption and a non-ignorable veriﬁcation bias model.
The goodness-of-ﬁt statistics suggest that the proposed models ﬁt the data well. From the data analysis
results, we concluded that the two screening tests for Alzheimer’s disease are not statistically signiﬁcant
in both the Indianapolis and Ibadan sites. The accuracy of the standard screening test is higher in
Indianapolis than in Ibadan.
The current paper has one limitation due to the limitation of the available data. There are three
reasons why subjects did not have unveriﬁed disease status: (1) they were not selected to undergo
veriﬁcation; (2) they were selected but were too frail to undergo veriﬁcation; and (3) they were selected
but refused to undergo veriﬁcation. Unfortunately, since we do not have information on which category
a unveriﬁed subject belongs to, we have lumped the three categories into one unveriﬁed group. It is
likely that the veriﬁcation mechanism for those subjects who were not selected for veriﬁcation would be
ignorable. If we had had such data, we would have build a better model for the veriﬁcation mechanism
that would have speciﬁed a non-ignorable veriﬁcation mechanism for unveriﬁed subjects who were
selected but either too frail or refused to undergo veriﬁcation and would have speciﬁed a diﬀerent
ignorable veriﬁcation mechanism for unveriﬁed subjects who were not selected to undergo veriﬁcation.
It is worth to note that the current paper jointly modelled the non-ignorable parameter α and out-
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come data, and the identiﬁability of α comes from the parametric model assumption for the veriﬁcation
bias mechanism that is unveriﬁable. An alternative approach to deal with non-ignorable veriﬁcation
bias is to apply the semi-parametric sensitivity analysis models proposed by Scharfstein et al (2002) for
non-ignorable drop-outs. It is a future research topic to compare these two approaches.
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Table 1: Cross-classiﬁcation of two screening tests
Indianapolis Site
T1 = 1 T1 = 2 T1 = 3
T2 = 1 T2 = 2 T2 = 3 T2 = 1 T2 = 2 T2 = 3 T2 = 1 T2 = 2 T2 = 3
V=1 D=0 37 4 10 14 0 9 8 2 25
D=1 0 0 0 1 0 3 5 0 31
V=0 287 45 53 11 3 12 6 0 22
Total 324 49 63 26 3 24 19 2 78
Ibadan Site
T1 = 1 T1 = 2 T1 = 3
T2 = 1 T2 = 2 T2 = 3 T2 = 1 T2 = 2 T2 = 3 T2 = 1 T2 = 2 T2 = 3
V=1 D=0 33 17 25 3 5 38 2 3 111
D=1 0 1 1 0 0 2 0 0 17
V=0 146 85 119 4 3 37 1 1 47
Total 179 103 145 7 8 77 3 4 175
Table 2: Observed Data
T1 = 1 . . . T1 = K
T2 = 1 . . . T2 = K . . . T2 = 1 . . . T2 = K
V=1 D=1 s11 . . . s1K . . . sK1 . . . sKK
D=0 r11 . . . r1K . . . rK1 . . . rKK
V=0 u11 . . . u1K . . . uK1 . . . uKK
Total n11 . . . n1K . . . nK1 . . . nKK
Table 3: The ML estimates for α and β in the non-ignorable model and the goodness-of-ﬁt
α β0 β1 β2 β3 β4 Goodness-of-ﬁt
Indianapolis Site
-2.86 3.27 -4.59 -1.68 -0.58 -0.42 0.188
Ibadan Site
-2.84 2.14 -3.18 -1.43 -0.34 0.14 0.119
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Table 4: The ML estimates under the ROC curve areas of the screening tests in Indianapolis and Ibadan
sites
Veriﬁcation model A1 Var(A1) A2 Var(A2) Cov(A1, A2) 95% Normal CI
Indianapolis Site
The ignorable
assumption 0.87 0.0036 0.78 0.0019 0.0011 (-0.022, 0.203)
The non-ignorable
model 0.69 0.0890 0.70 0.0414 0.054 (-0.303, 0.283)
Ibadan Site
The ignorable
assumption 0.68 0.0067 0.61 0.0032 0.0024 (-0.070, 0.210)
The non-ignorable
model 0.53 0.0295 0.54 0.0112 0.0096 (-0.297, 0.277)
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